BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6129 related articles for article (PubMed ID: 24055443)

  • 21. The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent.
    Haude M; Lee SW; Worthley SG; Silber S; Verheye S; Erbs S; Rosli MA; Botelho R; Meredith I; Sim KH; Stella PR; Tan HC; Whitbourn R; Thambar S; Abizaid A; Koh TH; Den Heijer P; Parise H; Cristea E; Maehara A; Mehran R
    JACC Cardiovasc Interv; 2013 Apr; 6(4):334-43. PubMed ID: 23523459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparable clinical safety and efficacy of biodegradable versus durable polymer paclitaxel eluting stents despite shorter dual antiplatelet therapy: insights from a multicenter, propensity score-matched registry.
    Buszman PP; Orlik B; Trela B; Milewski K; Kozlowski M; Pruski M; Drzewiecki J; Peppas A; Granada JF; Kaluza GL; Buszman PE
    Catheter Cardiovasc Interv; 2013 Sep; 82(3):E155-62. PubMed ID: 23109067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of long-term follow-up with neointimal coverage and stent apposition after sirolimus-eluting stent implantation by optical coherence tomography.
    Li S; Gai L; Yang T; Zhang L; Xu X; Bai Q; Xu H; Wang Y
    Catheter Cardiovasc Interv; 2013 Apr; 81(5):768-75. PubMed ID: 22639418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An optical coherence tomography study of neointimal morphology and strut coverage at different time intervals from implantation of biodegradable polymer-coated sirolimus-eluting stents.
    Legutko J; Gil RJ; Buszman PE; Kaluza GL; Mintz GS; Roleder T; Krol M; Wojdyla R; Pawlowski T; Brzezinski M; Kondys M; Skwarna B; Jakala J; Zasada W; Partyka L; Dudek D
    Catheter Cardiovasc Interv; 2018 Aug; 92(2):302-309. PubMed ID: 29027737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
    Gao RL; Xu B; Lansky AJ; Yang YJ; Ma CS; Han YL; Chen SL; Li H; Zhang RY; Fu GS; Yuan ZY; Jiang H; Huo Y; Li W; Zhang YJ; Leon MB;
    EuroIntervention; 2013 May; 9(1):75-83. PubMed ID: 23685298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
    Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
    Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meta-analysis of bioabsorbable versus durable polymer drug-eluting stents in 20,005 patients with coronary artery disease: an update.
    Lupi A; Gabrio Secco G; Rognoni A; Lazzero M; Fattori R; Sheiban I; Sante Bongo A; Bolognese L; Agostoni P; Porto I
    Catheter Cardiovasc Interv; 2014 May; 83(6):E193-206. PubMed ID: 24478247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The OCT-ORION Study: A Randomized Optical Coherence Tomography Study Comparing Resolute Integrity to Biomatrix Drug-Eluting Stent on the Degree of Early Stent Healing and Late Lumen Loss.
    Lee SWL; Tam FCC; Lam SCC; Kong SL; Shea CP; Chan KKW; Wong MKL; Chan MPH; Wong AYT; Yung ASY; Lam YM; Zhang LW; Wu KKY; Mintz GS; Maehara A
    Circ Cardiovasc Interv; 2018 Apr; 11(4):e006034. PubMed ID: 29654119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial.
    Kim JS; Jang IK; Fan C; Kim TH; Kim JS; Park SM; Choi EY; Lee SH; Ko YG; Choi D; Hong MK; Jang Y
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1240-7. PubMed ID: 20129551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drug-eluting stents.
    Guagliumi G; Musumeci G; Sirbu V; Bezerra HG; Suzuki N; Fiocca L; Matiashvili A; Lortkipanidze N; Trivisonno A; Valsecchi O; Biondi-Zoccai G; Costa MA;
    JACC Cardiovasc Interv; 2010 May; 3(5):531-9. PubMed ID: 20488410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of long-term in-stent vascular response between abluminal groove-filled biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent: 3-year OCT follow-up from the TARGET I trial.
    Xu B; Zhang YJ; Sun ZW; Qiao SB; Chen SL; Zhang RY; Pan DR; Pang S; Zhang Q; Xu L; Yang YJ; Leon MB; Gao RL
    Int J Cardiovasc Imaging; 2015 Dec; 31(8):1489-96. PubMed ID: 26208685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three-month evaluation of strut healing using a novel optical coherence tomography analytical method following bioresorbable polymer everolimus-eluting stent implantation in humans: the TIMELESS study.
    Vesga B; Hernandez H; Moncada M; Gasior P; Higuera S; Dager A; Arana C; Delgado JA; Généreux P; Maehara A; Granada JF
    Coron Artery Dis; 2017 Mar; 28(2):126-134. PubMed ID: 27879518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease.
    Puymirat E; Mangiacapra F; Peace A; Ntarladimas Y; Conte M; Bartunek J; Vanderheyden M; Wijns W; de Bruyne B; Barbato E
    Arch Cardiovasc Dis; 2013 Nov; 106(11):554-61. PubMed ID: 24231052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system.
    Costa JR; Abizaid A; Costa R; Feres F; Tanajura LF; Abizaid A; Mattos LA; Staico R; Siqueira D; Sousa AG; Bonan R; Sousa JE
    JACC Cardiovasc Interv; 2008 Oct; 1(5):545-51. PubMed ID: 19463357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Six-month outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold in treating single de novo lesions in human coronary artery.
    Wu Y; Shen L; Ge L; Wang Q; Qian J; Zhang F; Yao K; Huang D; Chen Y; Ge J
    Catheter Cardiovasc Interv; 2016 Mar; 87 Suppl 1():630-7. PubMed ID: 26864162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.
    Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Sabaté M; Smits PC; Kaiser C; D'Ascenzo F; Frati G; Mancone M; Genereux P; Stone GW
    J Am Coll Cardiol; 2014 Feb; 63(4):299-307. PubMed ID: 24211507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study.
    Li Y; Han Y; Zhang L; Jing Q; Wang X; Yan G; Ma Y; Wang G; Wang S; Chen X; Yang L; Zhu G; Liu H; Jiang T
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1127-33. PubMed ID: 22945767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 307.